Biologics & Biosimilars · Infectious Disease Therapeutics
Invivyd revenue, results and funding
Invivyd filed revenue of $53.4M for 2025.
Data updated Nov 20, 2026 · Back to the company report
$53.4MRevenue, 2025
−$52.5MNet income, 2025
Results by year
| Year | Revenue | Net income | Total assets | LANG_CR_S_M_TAX_EXPENSE | LANG_CR_S_M_BUYBACKS | LANG_CR_S_M_CAPEX | LANG_CR_S_M_SBC | LANG_CR_S_M_RND | LANG_CR_S_M_OPERATING_INCOME | LANG_CR_S_M_CASH |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $53.4M | −$52.5M | $276.9M | $0 | – | $155k | $11.6M | $38.3M | −$55.6M | $226.7M |
| 2024 | $25.4M | −$169.9M | $129.5M | $0 | $0 | $140k | $19.8M | $137.3M | −$176.9M | $69.3M |
| 2023 | $0 | −$198.6M | $229.2M | $0 | $1k | $615k | $18.7M | $158.7M | −$212.8M | $200.6M |
| 2022 | – | −$241.3M | $383.2M | $0 | $4k | $1.7M | $21.6M | $179.2M | −$248M | $92.1M |
| 2021 | – | −$226.8M | $620.1M | $0 | $0 | $84k | $17.8M | $182.9M | −$226.9M | $542.2M |
| 2020 | – | −$38.7M | $117.4M | – | – | – | – | – | – | $115M |
Sources: SEC
How to cite
Invivyd, Financials. Alion, Nov 20, 2026. https://alion.io/company/invivyd/financials
